Photo by matmacq from unsplash
Lenvatinib is an effective drug in advanced HCC. Its combination with the anti‐PD1 (programmed cell death protein 1) immune checkpoint inhibitor, pembrolizumab, has generated encouraging results in phase Ib and… Click to show full abstract
Lenvatinib is an effective drug in advanced HCC. Its combination with the anti‐PD1 (programmed cell death protein 1) immune checkpoint inhibitor, pembrolizumab, has generated encouraging results in phase Ib and is currently being tested in phase III trials. Here, we aimed to explore the molecular and immunomodulatory effects of lenvatinib alone or in combination with anti‐PD1.
Keywords:
death protein;
immunomodulatory effects;
programmed cell;
cell death;
effects lenvatinib
Journal Title: Hepatology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Hepatology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!